Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Titel:
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Auteur:
Schoenfeld, Jonathan D Giobbie-Hurder, Anita Ranasinghe, Srinika Kao, Katrina Z Lako, Ana Tsuji, Junko Liu, Yang Brennick, Ryan C Gentzler, Ryan D Lee, Carrie Hubbard, Joleen Arnold, Susanne M Abbruzzese, James L Jabbour, Salma K Uboha, Nataliya V Stephans, Kevin L Johnson, Jennifer M Park, Haeseong Villaruz, Liza C Sharon, Elad Streicher, Howard Ahmed, Mansoor M Lyon, Hayley Cibuskis, Carrie Lennon, Niall Jhaveri, Aashna Yang, Lin Altreuter, Jennifer Gunasti, Lauren Weirather, Jason L Mak, Raymond H Awad, Mark M Rodig, Scott J Chen, Helen X Wu, Catherine J Monjazeb, Arta M Hodi, F Stephen